Cargando…
Nilotinib-Induced Keratosis Pilaris
Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor (TKI) that is approved for the treatment of imatinib-resistant chronic myeloid leukaemia expressing the Bcr-Abl mutation. Cutaneous adverse drug reactions occur more frequently in patients using this medication. We present a case of...
Autores principales: | Leong, Wai Mun Sean, Aw, Chen Wee Derrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868941/ https://www.ncbi.nlm.nih.gov/pubmed/27194977 http://dx.doi.org/10.1159/000445676 |
Ejemplares similares
-
Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning
por: Tawil, Maya Halabi, et al.
Publicado: (2017) -
Nilotinib-induced generalized keratosis pilaris: Report of a rare case
por: Kowe, Priyanka Arun, et al.
Publicado: (2021) -
Oral Alitretinoin for the Treatment of Recalcitrant Pityriasis Rubra Pilaris
por: Schmitt, Laurenz, et al.
Publicado: (2011) -
Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
por: Koizumi, Tomonobu, et al.
Publicado: (2016) -
Solar Elastosis in Its Papular Form: Uncommon, Mistakable
por: Heng, Jun Khee, et al.
Publicado: (2014)